Gut microbiota as a potential key to modulating humoral immunogenicity of new platform COVID-19 vaccines
Signal Transduct Target Ther
.
2023 May 3;8(1):178.
doi: 10.1038/s41392-023-01445-0.
Authors
Hye Seong
1
2
3
,
Bo Kyu Choi
4
,
Young-Hee Han
5
,
Jun Hyoung Kim
6
,
Jeong-An Gim
7
,
Sooyeon Lim
1
2
3
,
Ji Yun Noh
1
2
3
,
Hee Jin Cheong
1
2
3
,
Woo Joo Kim
1
2
3
,
Joon Young Song
8
9
10
Affiliations
1
Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
2
Asia Pacific Influenza Institute, Korea University College of Medicine, Seoul, Republic of Korea.
3
Vaccine Innovation Center, Korea University College of Medicine, Seoul, Republic of Korea.
4
Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.
5
Department of Food and Nutrition, Chungbuk National University, Cheongju, Republic of Korea.
6
Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.
7
Medical Science Research Center, Korea University College of Medicine, Seoul, Republic of Korea.
8
Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea. infection@korea.ac.kr.
9
Asia Pacific Influenza Institute, Korea University College of Medicine, Seoul, Republic of Korea. infection@korea.ac.kr.
10
Vaccine Innovation Center, Korea University College of Medicine, Seoul, Republic of Korea. infection@korea.ac.kr.
PMID:
37137906
PMCID:
PMC10154741
DOI:
10.1038/s41392-023-01445-0
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
COVID-19 Vaccines / therapeutic use
COVID-19* / prevention & control
Gastrointestinal Microbiome*
Humans
Substances
COVID-19 Vaccines